Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 3Completed 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Immunoglobulin Light-chain Amyloidosis 3

Interventions

Dexamethasone 116Bortezomib 63Cyclophosphamide 51Lenalidomide 49Calcium Dobesilate 46Melphalan 37pomalidomide 36fludarabine 28Filgrastim 26fludarabine phosphate 23carfilzomib 22daratumumab 21Whole-Body Irradiation 17Granulocyte Colony-Stimulating Factor 17Mycophenolic Acid 15Antilymphocyte Serum 15dexamethasone acetate 14Tacrolimus 14Thalidomide 13Cyclosporine 13Busulfan 13Radiotherapy 12Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Stem Cell Transplantation 9Rituximab 9Etoposide 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × birtamimab × Plasma cell × Clear all
NCT02312206 2023-11-14

VITAL

Prothena Biosciences Ltd.

Phase 3 Terminated
260 enrolled 11 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT02613182 2019-05-16

OLE

Prothena Biosciences Ltd.

Phase 2 Terminated
34 enrolled 10 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03154047 2019-03-26

Study in Subjects With Light Chain (AL) Amyloidosis

Prothena Biosciences Ltd.

Phase 2 Terminated
80 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡